CA3209732A1 - Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof - Google Patents

Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof Download PDF

Info

Publication number
CA3209732A1
CA3209732A1 CA3209732A CA3209732A CA3209732A1 CA 3209732 A1 CA3209732 A1 CA 3209732A1 CA 3209732 A CA3209732 A CA 3209732A CA 3209732 A CA3209732 A CA 3209732A CA 3209732 A1 CA3209732 A1 CA 3209732A1
Authority
CA
Canada
Prior art keywords
polynucleotide sequence
seq
sequence
amino acid
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3209732A
Other languages
English (en)
French (fr)
Inventor
Drew Caldwell DENIGER
Lenka Victoria HURTON
Laurence James Neil COOPER
Donghyun JOO
Yaoyao Shi
An LU
Victor CARPIO
Matthew COLLINSON-PAUTZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alaunos Therapeutics Inc
Original Assignee
Alaunos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alaunos Therapeutics Inc filed Critical Alaunos Therapeutics Inc
Publication of CA3209732A1 publication Critical patent/CA3209732A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polyethers (AREA)
  • Fuel Cell (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3209732A 2021-02-25 2022-02-17 Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof Pending CA3209732A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163153862P 2021-02-25 2021-02-25
US63/153,862 2021-02-25
US202163159434P 2021-03-10 2021-03-10
US63/159,434 2021-03-10
US202163260409P 2021-08-19 2021-08-19
US63/260,409 2021-08-19
US202163260855P 2021-09-02 2021-09-02
US63/260,855 2021-09-02
US202263267421P 2022-02-01 2022-02-01
US63/267,421 2022-02-01
PCT/US2022/070690 WO2022183167A1 (en) 2021-02-25 2022-02-17 Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3209732A1 true CA3209732A1 (en) 2022-09-01

Family

ID=80628943

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3209732A Pending CA3209732A1 (en) 2021-02-25 2022-02-17 Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Country Status (8)

Country Link
US (1) US20240175047A1 (cg-RX-API-DMAC10.html)
EP (1) EP4298121A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024507929A (cg-RX-API-DMAC10.html)
KR (1) KR20230150336A (cg-RX-API-DMAC10.html)
AU (1) AU2022227085A1 (cg-RX-API-DMAC10.html)
CA (1) CA3209732A1 (cg-RX-API-DMAC10.html)
IL (1) IL305393A (cg-RX-API-DMAC10.html)
WO (1) WO2022183167A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159614A1 (en) * 2020-02-26 2023-05-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
WO2023150562A1 (en) * 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2023183344A1 (en) 2022-03-21 2023-09-28 Alaunos Therapeutics, Inc. Methods for identifying neoantigen-reactive t cell receptors
JP2025530339A (ja) * 2022-09-13 2025-09-11 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 変異型rasを標的化するためのt細胞受容体及びその組成物
WO2024163371A1 (en) * 2023-01-30 2024-08-08 Fred Hutchinson Cancer Center Binding proteins specific for mutant p53 and uses thereof
WO2024197072A2 (en) 2023-03-21 2024-09-26 Alaunos Therapeutics, Inc. Identification of neoantigen-reactive t cell receptors
AU2024241888A1 (en) * 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
CN117143823B (zh) * 2023-09-11 2024-07-16 皖南医学院第一附属医院(皖南医学院弋矶山医院) 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DK0973928T3 (da) 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
GB0712670D0 (en) 2007-06-29 2007-08-08 King S College London Isolated peptides and uses thereof
US9228180B2 (en) 2007-07-04 2016-01-05 Max-Delbruck-Centrum Fur Molekulare Medizin Polypeptide variants of sleeping beauty transposase
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
PT2692865E (pt) 2012-07-30 2015-02-06 Nbe Therapeutics Llc Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
SG10201913978RA (en) 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
JP6775515B2 (ja) 2015-03-11 2020-10-28 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム トランスポザーゼポリペプチド及びその使用
SG10201913868XA (en) 2015-09-15 2020-03-30 The United States Of America As Represented By The Secretary T cell receptors recognizing hla-cw8 restricted mutated kras
SG11201900654QA (en) 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
WO2018209115A1 (en) 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3635132A4 (en) * 2017-06-07 2021-05-26 Intrexon Corporation EXPRESSION OF NOVEL CELL MARKERS
AU2018321105B2 (en) 2017-08-21 2025-01-30 European Molecular Biology Laboratory Improved transposase polypeptide and uses thereof
AU2018335274B2 (en) 2017-09-20 2025-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II–restricted T cell receptors against mutated RAS
IL273515B2 (en) 2017-09-29 2026-03-01 Us Health T cell receptors that recognize mutated P53
JP7391015B2 (ja) 2017-09-29 2023-12-04 アメリカ合衆国 P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法
US12227554B2 (en) 2017-10-05 2025-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
MX2020005765A (es) 2017-12-04 2020-09-25 Us Health Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
WO2019160956A1 (en) * 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3561053A1 (en) * 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
AU2019263233B2 (en) 2018-05-01 2024-08-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors which recognize mutated EGFR
US20200129555A1 (en) 2018-10-24 2020-04-30 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
US20220033848A1 (en) * 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
WO2020154275A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
WO2020264269A1 (en) 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CA3168015A1 (en) 2020-02-12 2021-08-19 Noam LEVIN Hla class i-restricted t cell receptors against ras with g12d mutation
MX2022009825A (es) 2020-02-14 2022-10-13 Us Health Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
US20230159614A1 (en) 2020-02-26 2023-05-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation

Also Published As

Publication number Publication date
WO2022183167A1 (en) 2022-09-01
JP2024507929A (ja) 2024-02-21
KR20230150336A (ko) 2023-10-30
US20240175047A1 (en) 2024-05-30
EP4298121A1 (en) 2024-01-03
IL305393A (en) 2023-10-01
AU2022227085A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
US20240175047A1 (en) Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
JP7317793B2 (ja) 改変γδT細胞
EP3481867B1 (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
US12060394B2 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
JP7627080B2 (ja) B7h3キメラ抗原受容体を含む方法および組成物
US20210147800A1 (en) Methods for producing regulatory immune cells and uses thereof
JP2019536437A (ja) Hpv特異的結合分子
CA3053592A1 (en) Antibody targeting il-13ra2 and use thereof
KR20230010228A (ko) 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars)
TW202432581A (zh) 改善免疫細胞功能
US20250145950A1 (en) Methods for Activation and Expansion of T Cells
WO2022206994A1 (en) Engineered immune cells and uses thereof
WO2021232050A1 (en) Natural killer cell immunotherapy for the treatment or prevention of sars-cov-2 infection
US20240316201A1 (en) Engineered immune effector cells expressing exogenously introduced cytokines
EP4583905A1 (en) Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
US20230279350A1 (en) Dual car-t cells
CN117098772A (zh) 包含多顺反子表达盒的重组载体及其使用方法
HK40101165A (en) Engineered immune cells and uses thereof
WO2026085184A1 (en) Cd2 chimeric switch receptors and uses thereof for adoptive cell transfer immunotherapy
CN121896173A (zh) 表达外源肌苷单磷酸脱氢酶的真核细胞
HK40008962B (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
HK40008962A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof

Legal Events

Date Code Title Description
R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20241120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251210

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260526